Johnson & Johnson reports second-quarter 2023 earnings | Women

" Johnson & Johnson delivered strong results in the second quarter. We executed on our long-term business strategy by achieving significant clinical and regulatory milestones in our Pharmaceuticals and Medical Technology businesses," said Joe Wolk, Executive Vice President and Chief Financial Officer, Johnson & Johnson. "These advances provide a strong foundation for the company's long-term growth and reflect our dedication around the world. We will continue to invest in innovation that delivers transformative treatments for patients and delivers long-term value for shareholders."

Johnson & Johnson carries the aspiration to advance innovations to care for community health

Johnson & Johnson's second quarter of 2023 reported revenue growth of 6.3% to $25.5 billion with operating growth of 7.5%. Earnings per share (EPS) were $1.96, up 8.9%, and adjusted EPS was $2.80, up 8.1%. The company just announced a third quarter 2023 cash dividend of $1.19/share. Listed share price: $172.94 (August 16, 2023). Ex-dividend date: August 25, 2023. Dividend payment date: September 7, 2023. Yield: 13.76% with a margin of 1:20

The Johnson & Johnson (NYSE:JNJ) brand ticks all the important boxes: dividend growth, high yield, solid and stable yield.

Johnson & Johnson reported second-quarter revenue and adjusted earnings that beat Wall Street expectations on July 20, 2023, as sales from the company's medical technology business surged.

The medical technology division provides devices for surgery, orthopedics and vision. The company is benefiting from a rebound in demand for non-urgent surgeries among older adults who had postponed such procedures during the COVID-19 pandemic.

Here's how J&J's results compared to Wall Street expectations, based on a survey of analysts by Refinitiv:Earnings per share: $2.80 adjusted, vs. $2.62 expected.Revenue: $25.53 billion, vs. $24.63 billion expected

Johnson & Johnson said second-quarter sales increased 6.3% from the same period last year. The pharmaceutical giant reported net income of $5.14 billion, or $1.96 per share. That compares with net income of $4.8 billion, or $1.80 per share, in the same period last year.

The company now forecasts full-year revenue of $98.80 billion to $99.80 billion, about $1 billion higher than its April 2023 forecast. Johnson & Johnson raised its 2023 adjusted earnings outlook to $10.70 to $10.80 a share, from its previous forecast of $10.60 to $10.70 a share.

Johnson & Johnson Advances New Digital Healthcare Solutions

Johnson & Johnson has a market capitalization of $449.47 billion, a P/E ratio of 35.04, a price-to-earnings-growth ratio of 2.92, and a beta of 0.54. The healthcare stock had a 12-month low of $150.11 and a high of $181.04. The company has a 50-day simple moving average of $165.20 and a 200-day simple moving average of $161.17. Johnson & Johnson has a debt-to-equity ratio of 0.44, a current ratio of 1.12, and a quick ratio of 0.88.

Revenue for the company's medical devices business rose to $7.79 billion, up 12.9% from the second quarter of 2022. Johnson & Johnson said its December 2022 acquisition of Abiomed, a cardiovascular medical technology company, helped fuel that growth.

"Johnson & Johnson's strong performance in the second quarter and first half of 2023 is a testament to the hard work and commitment of our colleagues around the world ," said Joaquin Duato, Chairman of the Board and Chief Executive Officer. "We continue to focus on Pharmaceutical and MedTech innovation."

Source: https://phunu.nld.com.vn/lam-dep/johnson-johnson-bao-cao-thu-nhap-quy-2-nam-2023-20230822220616066.htm